James William Rogers Sells 31,780 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 31,780 shares of Tempus AI stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40. Following the completion of the sale, the chief financial officer now directly owns 189,320 shares of the company’s stock, valued at approximately $15,586,715.60. The trade was a 14.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

James William Rogers also recently made the following trade(s):

• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The shares were sold at an average price of $67.57, for a total transaction of $588,669.84.
• On Monday, December 16th, James William Rogers sold 1,468 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $59,057.64.
• On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The shares were sold at an average price of $42.30, for a total transaction of $3,511,957.50.

Tempus AI Stock Performance

NASDAQ:TEM opened at $68.09 on Friday. The firm’s 50-day moving average is $50.29 and its 200-day moving average is $51.65. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TEM shares. Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a report on Tuesday, January 14th. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $58.55.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC increased its stake in Tempus AI by 141,400.0% in the third quarter. International Assets Investment Management LLC now owns 70,750 shares of the company’s stock valued at $4,004,000 after acquiring an additional 70,700 shares during the period. Dakota Wealth Management bought a new stake in Tempus AI in the third quarter valued at about $1,185,000. Janney Capital Management LLC bought a new stake in Tempus AI in the third quarter valued at about $385,000. Vestor Capital LLC bought a new stake in Tempus AI in the third quarter valued at about $153,000. Finally, ARK Investment Management LLC increased its stake in Tempus AI by 355.0% in the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after acquiring an additional 1,855,459 shares during the period. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.